Claims for Patent: 8,414,922

Summary for Patent: 8,414,922

Title:	Sublingual films
Abstract:	The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
Inventor(s):	Bryson; Nathan John (Toronto, CA), Giovinazzo; Anthony John (Oakville, CA), Barnhart; Scott David (York, PA), Koons; Michael Clinton (York, PA)
Assignee:	Cynapsus Therapeutics, Inc. (Toronto, CA) ARx, LLC (Glen Rock, PA)
Application Number:	13/445,656
Patent Claims:	1. A pharmaceutical composition in unit dosage form formulated for sublingual administration, wherein said unit dosage form is a film comprising: (A) a first layer comprising: (i) from 10 to 75% (w/w) apomorphine hydrochloride; (ii) from 0.5 to 10% (w/w) a low molecular weight polymer having a weight average molecular weight of from 5 KDa to 50 KDa selected from hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, and methyl cellulose; and (iii) from 4 to 35% (w/w) a high molecular weight polymer having a weight average molecular weight of greater than 60 KDa selected from hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, and methyl cellulose, and (B) a second layer comprising: (iv) from 6 to 65% (w/w) a pH neutralizing agent that is an organic base having a pKa of 5.+-.2, and (v) from 15 to 50% (w/w) of a high molecular weight polymer having a weight average molecular weight of greater than 60 KDa selected from hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, and methyl cellulose, wherein said first layer comprises from 2 to 60 mg of apomorphine hydrochloride, wherein, following sublingual administration to subjects, said unit dosage form produces an average circulating concentration of 3 to 6 ng/mL within a period of from 7 to 20 minutes, and wherein said unit dosage form when placed in 1 mL of unbuffered water at pH 7 results in a solution having a pH of between 4.5 and 6.5. 2. The pharmaceutical composition of claim 1, wherein said film further comprises from 3 to 12% (w/w) plasticizing agent. 3. The pharmaceutical composition of claim 2, wherein said plasticizing agent is a polyol, oleic acid, or triacetin. 4. The pharmaceutical composition of claim 3, wherein said plasticizing agent is a polyol selected from sorbitol, mannitol, maltitol, xylitol, glycerol, propylene glycol, and polyethylene glycol. 5. The pharmaceutical composition of claim 1, wherein said film comprises from 1 to 50% (w/w) hydrolyzed starch. 6. The pharmaceutical composition of claim 5, wherein said hydrolyzed starch is a dextrin or a maltodextrin. 7. The pharmaceutical composition of claim 1, wherein said film further comprises an antioxidant. 8. The pharmaceutical composition of claim 7, wherein said film further comprises from 0.05 to 2.5% (w/w) metabisulfite. 9. The pharmaceutical composition of claim 1, wherein said film further comprises from 0.2 to 5% (w/w) of a permeation enhancer. 10. The pharmaceutical composition of claim 9, wherein said permeation enhancer is glycerol monostearate. 11. The pharmaceutical composition of claim 1, wherein said low molecular weight polymer is hydroxypropyl methyl cellulose, hydroxypropyl cellulose, or hydroxyethyl cellulose. 12. The pharmaceutical composition of claim 11, wherein said hydroxypropyl methylcellulose has about 20% to about 35% methoxyl substitution and about 5% to about 15% hydroxypropyl substitution. 13. The pharmaceutical composition of claim 1, wherein said high molecular weight polymer is hydroxypropyl methyl cellulose or hydroxyethyl cellulose. 14. The pharmaceutical composition of claim 13, wherein said high molecular weight polymer is hydroxypropyl methyl cellulose having about 20% to about 35% methoxyl substitution and about 5% to about 15% hydroxypropyl substitution. 15. The pharmaceutical composition of claim 13, wherein said high molecular weight polymer is hydroxyethyl cellulose having a weight average molecular weight of from 60 KDa to 1,000 KDa. 16. The pharmaceutical composition of claim 1, wherein said organic base selected from pyridoxine, citrate, acetate, and histidine. 17. The pharmaceutical composition of claim 1, wherein following sublingual administration to a subject said unit dosage form produces an average circulating concentration of at least 3 ng/mL within a period of from 5 to 15 minutes. 18. A method of treating Parkinson's disease in a subject, said method comprising sublingual administration of a pharmaceutical composition of claim 1 in an amount effective to treat said subject. 19. The pharmaceutical composition of claim 16, wherein said organic base is pyridoxine. 20. The pharmaceutical composition of claim 1, wherein said unit dosage form comprises 12.+-.3 mg of apomorphine hydrochloride. 21. The pharmaceutical composition of claim 1, wherein said unit dosage form comprises 22.+-.4 mg of apomorphine hydrochloride. 22. The pharmaceutical composition of claim 1, wherein said unit dosage form comprises 30.+-.5 mg of apomorphine hydrochloride. 23. The pharmaceutical composition of claim 1, wherein said unit dosage form comprises 35.+-.5 mg of apomorphine hydrochloride.